SU‐G‐JeP1‐06: Correlation of Lung Tumor Motion with Tumor Location Using Electromagnetic Tracking

Abstract

Purpose:It is well known that lung tumors move with respiration. However, most measurements of lung tumor motion have studied long treatment times with intermittent imaging; those populations may not necessarily represent conventional LINAC patients. We summarized the correlation between tumor motion and location in a multi‐institutional trial with electromagnetic tracking, and identified the patient cohort that would most benefit from respiratory gating.Methods:Continuous electromagnetic transponder data (Varian Medical, Seattle, WA) of lung tumor motion was collected from 14 patients (214 total fractions) across 3 institutions during external beam radiation therapy in a prospective clinical trial (NCT01396551). External intervention from the clinician, such as couch shifts, instructed breath‐holds, and acquisition pauses, were manually removed from the 10 Hz tracking data according to recorded notes. The average three‐dimensional displacement from the breathing cycle's end‐expiratory to end‐inhalation phases (peak‐to‐peak distance) of the transponders’ isocenter was calculated for each patient's treatment. A weighted average of each isocenter was used to assess the effects of location on motion. A total of 14 patients were included in this analysis, grouped by their transponders’ location in the lung: upper, medial, and lower.Results:8 patients had transponders in the upper lung, and 3 patients each in the medial lobe and lower lung. The weighted average ± standard deviation of all peak‐to‐peak distances for each group was: 1.04 ± 0.39 cm in the lower lung, 0.56 ± 0.14 cm in the medial lung, and 0.30 ± 0.06 cm in the upper lung.Conclusion:Tumors in the lower lung are most susceptible to excessive motion and daily variation, and would benefit most from continuous motion tracking and gating. Those in the medial lobe might be at moderate risk. The upper lobes have limited motion. These results can guide different motion management strategies between lung tumor locations.This is part of an NIH‐funded prospective clinical trial (NCT01396551), using an electromagnetic transponder tracking system and additional funding from Varian Medical (Seattle, WA).